Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, April 15, 2020
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
[ Wed, Apr 15th 2020
] - WOPRAI
Alethia Young Upgraded (ARWR) to Buy and Held Target at $60 on, Apr 15th, 2020
Alethia Young of Cantor Fitzgerald, Upgraded "Arrowhead Pharmaceuticals, Inc." (ARWR) to Buy and Held Target at $60 on, Apr 15th, 2020.
Alethia has made no other calls on ARWR in the last 4 months.
There are 3 other peers that have a rating on ARWR. Out of the 3 peers that are also analyzing ARWR, 2 agree with Alethia's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Mani Foroohar of "SVB Leerink" Upgraded from Sell to Hold on, Tuesday, March 24th, 2020
- Salveen Richter of "Goldman Sachs" Initiated at Hold and Held Target at $45 on, Tuesday, March 17th, 2020
This is the rating of the analyst that currently disagrees with Alethia
- Mayank Mamtani of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $57 on, Friday, March 13th, 2020
